GSK/Theravance Press On With LABA After Cmtes. Cut Asthma Indication

Many pharmaceutical firms' corporate plans for developing new asthma products that combine long-acting beta agonists with inhaled corticosteroids are not seriously affected by the recommendation of three FDA advisory committees to eliminate the asthma indication for single-entity LABA products